RxDoctor Payments DataLook up a doctor →

Kimberly Wagner, MD

Neurology · Colorado Springs, CONPI 1922325497

Payments from drug & device makers

$2,265,945in general payments, 2019–2025

Across 2,056 payments — averaging $1102.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1.4M
  • Teva Pharmaceuticals USA, Inc.$199K
  • AstraZeneca$155K
  • Adamas Pharmaceuticals, Inc.$151K
  • AbbVie$60K
  • Genentech, Inc.$37K
  • plus $276K from 54 others
$17,962in research payments, 2019–2025

Across 7 payments — averaging $2566.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$18K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis175$1,387,897
Teva Pharmaceuticals USA, Inc.149$198,595
AstraZeneca63$154,933
Adamas Pharmaceuticals, Inc.41$151,451
AbbVie(2 entities)223$59,827
Genentech, Inc.9$36,608
Otsuka Pharmaceutical Development & Commercialization, Inc.2$35,924
Sanofi82$32,318
Biohaven Pharmaceutical Holding Company Ltd.30$31,498
Bristol Myers Squibb75$31,344
Pfizer112$27,783
EMD Serono, Inc.139$21,768
Biohaven Pharmaceuticals, Inc.59$15,267
Biogen149$15,055
UCB Biosciences Inc.8$13,361
Avanir Pharmaceuticals, Inc.4$10,385
Sanofi US Services Inc.1$8,500
TG Therapeutics, Inc.73$6,752
Eisai Inc.24$6,263
E.r. Squibb & Sons, L.L.C.10$1,566
Livanova USA, Inc.6$1,457
Lundbeck LLC16$1,447
Amgen(2 entities)35$1,212
Boston Scientific11$1,190
Neurocrine Biosciences, Inc.92$1,088
Ares Trading SA12$941
Acorda Therapeutics, Inc20$786
Genentech USA, Inc.23$761
UCB, Inc.28$749
Merz Pharmaceuticals, LLC39$730
Lilly USA, LLC42$718
Neurelis, Inc.15$629
SK Life Science, Inc.21$515
Tanabe Pharma America, Inc.23$445
Jazz Pharmaceuticals Inc.14$379
Argenx US, Inc.11$370
Acadia Pharmaceuticals Inc17$319
GRT US Holding, Inc.9$316
Mallinckrodt Hospital Products Inc.9$310
Abbott13$283
Supernus Pharmaceuticals, Inc.10$251
Ipsen Biopharmaceuticals, Inc12$244
MDD US Operations, LLC9$233
Kyowa Kirin, Inc.10$224
CSL Behring8$222
Otsuka America Pharmaceutical, Inc.4$195
Catalyst Pharmaceuticals, Inc.7$194
Sunovion Pharmaceuticals Inc.15$185
Averitas Pharma Inc.4$184
Vanda Pharmaceuticals Inc.8$180
Medtronic2$169
Axsome Therapeutics, Inc.3$142
Alnylam Pharmaceuticals Inc.5$123
Greenwich Biosciences, Inc.5$123
Novo Nordisk1$118
ANI Pharmaceuticals, Inc.5$110
Octapharma USA, Inc.4$95
Avion Pharmaceuticals4$89
Harmony Biosciences LLC3$81
Akcea Therapeutics, Inc.5$72

How this compares

$2,265,945 in reported general payments places this provider in the 95th percentile of 334 neurology providers in Colorado.

See all neurology providers in Colorado →

Medicare billing

Part B allowed, 2024
$867,728
Medicare patients
542
Services billed
73,684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Colorado Springs

See the full list for Colorado →

Where these figures come from

Is this you, or does something look wrong? →